OR51E1 and lung carcinoma: Furthemore, ADGRE3 and OR51E1 expression was positively correlated with sensitivity to the drugs cisplatin, ribociclib, and pevonedistat, chemotherapeutics commonly used or being investigated in clinical trials for lung cancer [42, 43, 44].